Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

OcuTerra Therapeutics

Request full access

Developing a novel eye drop, designed to treat diabetic eye disease

Boston, United StatesFounded 2020Biotech & Life Sciences

About OcuTerra Therapeutics

OcuTerra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative drugs to treat ophthalmic diseases. The company's flagship product, OTT166, is a novel topical integrin inhibitor eye drop designed to transform the standard of care for conditions such as diabetic retinopathy. OcuTerra primarily serves patients suffering from debilitating eye diseases, aiming to provide more effective and less invasive treatment options compared to current standards. Operating in the ophthalmology market, the company leverages its extensive expertise in biotechnology and drug development to bring cutting-edge solutions to eye care. The business model revolves around advancing its drug pipeline through clinical trials, securing regulatory approvals, and eventually commercializing its products. Revenue generation is expected to come from the sales of these innovative treatments once they reach the market. The company is supported by a team of experienced leaders and advisors in the fields of biotechnology and ophthalmology, ensuring a strong foundation for its ambitious goals.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
24.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Dec 2023 $6.7M $175M Undisclosed ↗
SERIES BOther financing Nov 2021 $35M $140M Undisclosed ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

OcuTerra Therapeutics website traffic

Latest recorded traffic for OcuTerra Therapeutics is 850 monthly website visits, down 15% over the last three months. OcuTerra Therapeutics's team grew 0% over the past year.

Latest monthly visits850 3-month web change-15% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

OcuTerra Therapeutics in the Boston ecosystem

Live from Dealroom

The OcuTerra Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Boston HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about OcuTerra Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See OcuTerra Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.